ML-180
Modify Date: 2025-08-25 10:20:32
ML-180 structure
|
Common Name | ML-180 | ||
|---|---|---|---|---|
| CAS Number | 863588-32-3 | Molecular Weight | 388.891 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C20H25ClN4O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of ML-180ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers[1][2]. |
| Name | 6-[4-(3-Chlorophenyl)-1-piperazinyl]-3-cyclohexyl-2,4(1H,3H)-pyri midinedione |
|---|---|
| Synonym | More Synonyms |
| Description | ML-180 (SR1848) is a potent orphan nuclear receptor liver receptor homolog 1 (LRH-1; NR5A2) inverse agonist with an IC50 of 3.7 µM. ML-180 is inactive for steroidogenic factor-1 (SF-1; NR5A1; IC50>10 µM). ML-180 has the potential for LRH-1-dependent cancers[1][2]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 3.7 µM (LRH-1)[1] |
| In Vitro | ML-180 (SR1848; 0.01-100 µM; 48 hours) shows diminished capacity to proliferate at concentrations above 1 μM, and the EC50 being roughly 2.8 μM in Huh-7 cells. ML-180 inhibits cell proliferation in an LRH-1-dependent manner[2]. ML-180 (0.5-5 µM; 24 hours) shows a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells, but has little effect on repression in SK-OV-3 cells[2]. ML-180 (5 µM; 24 hours) leads to a rapid decrease of LRH-1 expression and efficiently represses endogenous LRH-1 signaling[2]. ML-180 (0.5-5 µM; 24 hours) inhibits LRH-1 mRNA expression in a dose-dependent manner[2]. ML-180 (5 μM; 2 hours) rapidly and significantly decreases the mRNA levels of LRH-1 receptor and its downstream targets (CYP19, GATA3, and GATA4) in Huh-7 and HepG2 cells[2]. Cell Proliferation Assay[2] Cell Line: Huh-7 cells Concentration: 0.01, 0.1, 1, 10, 100 µM Incubation Time: 48 hours Result: Showed diminished capacity to proliferate at concentrations above 1 μM. Cell Cycle Analysis[2] Cell Line: Huh-7 cells Concentration: 0.5, 1, 5 µM Incubation Time: 24 hours Result: Showed a significant inhibition of cyclin-D1 and cyclin-E1 expression in hepatic cells. Western Blot Analysis[2] Cell Line: Huh-7 cells Concentration: 5 µM Incubation Time: 24 hours Result: Significantly reduced the LRH-1 protein levels. RT-PCR[2] Cell Line: Huh-7 cells Concentration: 0.5, 1, 5 µM Incubation Time: 24 hours Result: Inhibited LRH-1 mRNA expression in a dose-dependent manner. |
| In Vivo | ML-180 (SR1848; 30 mg/kg; i.p.; daily; for 10 days) has a statistically significant decrease of both LRH-1 and SHP mRNA in adrenal glands and pancreatic tissue[2]. Animal Model: 8-week-old C57Bl/6J mice[2] Dosage: 30 mg/kg Administration: IP; daily; for 10 days Result: Had a statistically significant decrease of both LRH-1 and SHP mRNA in adrenal glands and pancreatic tissue. |
| References |
[1]. Busby S, et al. Discovery of Inverse Agonists for the Liver Receptor Homologue-1 (LRH1; NR5A2). |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Molecular Formula | C20H25ClN4O2 |
| Molecular Weight | 388.891 |
| Exact Mass | 388.166595 |
| PSA | 61.60000 |
| LogP | 4.43 |
| Index of Refraction | 1.619 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Codes | Xn |
| RIDADR | NONH for all modes of transport |
| 6-[4-(3-Chlorophenyl)-1-piperazinyl]-3-cyclohexyl-2,4(1H,3H)-pyrimidinedione |
| 2,4(1H,3H)-Pyrimidinedione, 6-[4-(3-chlorophenyl)-1-piperazinyl]-3-cyclohexyl- |